

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (Cancelled)
3. (Currently amended) A synthetic peptide ~~of about 50 to about 90 amino acids~~, which comprises
- (a) a ~~promiscuous~~ helper T cell epitope ~~[[Th]]~~,
 - (b) an IgE-CH3 domain antigen peptide, wherein said IgE-CH3 domain antigen peptide i) is ~~between about 25 and about 29 amino acids in length~~ ii) contains two cysteine residues separated by ~~about 23 amino acid residues~~, and iii) is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:84 ~~and an immunologically functional analog thereof~~, wherein from one to four of the residues in SEQ ID NO:5 is conservatively substituted ~~or deleted~~; and optionally
 - (c) an immunostimulatory invasin domain, SEQ ID NO: 13,

wherein the synthetic peptide induces anti-IgE antibody production in a mammal.

- 4-6. (Cancelled)
7. (Currently amended) ~~[[A]]~~The synthetic peptide of claim 3, wherein said helper T cell epitope~~[[Th]]~~ is an SSAL epitope.
- 8-9. (Cancelled)
10. (Previously presented) ~~[[A]]~~The synthetic peptide of claim 3, wherein said helper T cell epitope~~[[Th]]~~ has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12, SEQ ID NOS: 61-82, and SEQ ID NO: 89.

- 11-28. (Cancelled)